Sleijfer S, Verweij J. The Price of success: cost-effectiveness of molecularly targeted agents. Clin Pharmacol Ther. 2009 Feb; 85(2): 136-138.

2009 Sleijfer S, Verweij J. The Price of success: cost-effectiveness of molecularly targeted agents. Clin Pharmacol Ther. 2009 Feb; 85(2): 136-138. Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FW, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJ; on behalf of the CURAMA study group. Circulating endothelial cells: a potential parameter of organ damage in sickle cel anemia? Blood Cells Mol Dis. 2009 Jul-Aug;43(1):63-7. Epub 2009 Apr 7. Strijbos MH, Kraan J, Lamers CHJ, Sleijfer S, Gratama JW. Quantification of circulating endothelial cells by flow cytomerty. Clin Cancer Res 2009 May 15;15(10); 3640; author reply 3640-1. Strijbos MH, Verhoef C, Gratama JW, Sleijfer S. On the Origin of (CD105+) circulating endothelial cells. Thromb Haemost. 2009;102(2); 347-351. Jager A, Verweij J, Sleijfer S. Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer. Nat Rev Clin Oncol 2009 Oct; 6(10); 563-5 Kuijper TM, Ruigrok-Ritstier K, Verhoef-Post M, Piersma D, Bruysters MW, Berns EM, Themmen AP. LH receptor gene expression is essentially absent in breast tumor tissue: implications for treatment. Mol Cell Endocrinol. 2009 Apr 10;302(1):58-64. Epub 2009 Jan 20. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009 Mar 24;100(6):971-8. Epub 2009 Feb 24. Kuijper A, Snijders AM, Berns EM, Kuenen-Boumeester V, van der Wall E, Albertson DG, van Diest PJ. Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours. Cell Oncol. 2009;31(1):31-9. Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Res Treat. 2009 Jul;116(2):263-71. Epub 2008 Jul 16. Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009 Jan;113(2):275-83. Epub 2008 Mar 4. Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res Treat. 2009 Jan;113(2):253-60. Epub 2008 Feb 26.

de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009 Aug 13;361(7):653-63. Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Li Y, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J; kconfab Investigators; AOCS Group, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Justenhoven C, Ko YD, Haas S, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Turnbull C, Hines S, Renwick A, Rahman N, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang- Gohrke S, Shen CY, Wang HC, Yu JC, Chen ST, Bermisheva M, Nikolaeva T, Khusnutdinova E, Humphreys MK, Morrison J, Platte R, Easton DF; Breast Cancer Association Consortium. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35- rs13387042. J Natl Cancer Inst. 2009 Jul 15;101(14):1012-8 Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus- Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009 Aug 10;27(23):3764-71. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Southey MC, Hopper JL, Apicella C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk MP, Tollenaar RA, Devilee P, Chanock S, Lissowska J, Brinton L, Peplonska B, Czene K, Hall P, Li Y, Liu J, Balasubramanian S, Rafii S, Reed MW, Pooley KA, Conroy D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SH, Shen CY, Wang HC, Yu JC, Wu PE, Anton-Culver H, Ziogoas A, Egan K, Newcomb P, Titus- Ernstoff L, Trentham Dietz A, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K, Cannon-Albright LA, Wong J; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Spurdle AB, Beesley J, Pharoah PD, Easton DF, Garcia-Closas M; Breast Cancer Association Consortium. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1610-6. Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C. Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hered Cancer Clin Pract. 2009 Mar 31;7(1):6. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maranian M, Pooley KA, Luben R, Eccles D, Evans DG, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Stratton MR, Rahman N, Jacobs K, Prentice R, Anderson GL, Rajkovic A, Curb JD, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver WR, Bojesen S, Nordestgaard BG, Flyger H,

Dörk T, Schürmann P, Hillemanns P, Karstens JH, Bogdanova NV, Antonenkova NN, Zalutsky IV, Bermisheva M, Fedorova S, Khusnutdinova E; SEARCH, Kang D, Yoo KY, Noh DY, Ahn SH, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Garcia-Closas M, Lissowska J, Brinton L, Peplonska B, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Hopper JL, Southey MC, Smith L, Spurdle AB, Schmidt MK, Broeks A, van Hien RR, Cornelissen S, Milne RL, Ribas G, González-Neira A, Benitez J, Schmutzler RK, Burwinkel B, Bartram CR, Meindl A, Brauch H, Justenhoven C, Hamann U; GENICA Consortium, Chang-Claude J, Hein R, Wang-Gohrke S, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kataja V, Olson JE, Wang X, Fredericksen Z, Giles GG, Severi G, Baglietto L, English DR, Hankinson SE, Cox DG, Kraft P, Vatten LJ, Hveem K, Kumle M, Sigurdson A, Doody M, Bhatti P, Alexander BH, Hooning MJ, van den Ouweland AM, Oldenburg RA, Schutte M, Hall P, Czene K, Liu J, Li Y, Cox A, Elliott G, Brock I, Reed MW, Shen CY, Yu JC, Hsu GC, Chen ST, Anton-Culver H, Ziogas A, Andrulis IL, Knight JA; kconfab; Australian Ovarian Cancer Study Group, Beesley J, Goode EL, Couch F, Chenevix-Trench G, Hoover RN, Ponder BA, Hunter DJ, Pharoah PD, Dunning AM, Chanock SJ, Easton DF. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009 May;41(5):585-90. van Dooren S, Duivenvoorden HJ, Passchier J, Bannink M, Tan MB, Oldenmenger WH, Seynaeve C, van der Rijt CC. The Distress Thermometer assessed in women at risk of developing hereditary breast cancer. Psychooncology. 2009 Oct;18(10):1080-7. Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X; kconfab Investigators; AOCS Group; Swedish BRCA1 and BRCA2 Study Collaborators, Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seyneave C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ; HEBON, Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G; Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat. 2009 Sep;117(2):371-9. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 2009;48(1):76-85. Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, Martens JW. Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group. Eur J Cancer. 2009 Jan;45(1):74-81. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M; EORTC PathoBiology Group. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009 Feb;45(3):335-346. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW.

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res. 2009 Jan 1;15(1):315-323. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009 Jan 7;101(1):61-66. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009 Feb 1;27(4):542-549. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar;114(2):287-299 Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA. Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer. Cancer Res. 2009 May 1;69(9):3795-801 Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolic L. Identification of a putative protein profile associating with tamoxifen therapy-resistance in breast cancer. Mol Cell Proteomics. 2009 Jun;8(6):1278-1294 Martens JW, Margossian AL, Schmitt M, Foekens J, Harbeck N. DNA methylation asa biomarker in breast cancer. Future Oncol. 2009 Oct;5(8):1245-56. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009 Dec 24;462(7276):1005-1010. Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers H. Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol Chem. 2009 Dec 18;284(51):35308-13. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009 Dec;118(3):455-468. Van Agthoven T, Sieuwerts A, Meijer D, Meijer-van Gelder M, Van Agthoven T, Sarwari R, Sleijfer S, Foekens J, Dorssers L.

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer. 2009 Dec 4. Van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer. 2009 Dec 1;101(11):1824-1832. Wasielewski M, Riaz M, Vermeulen J, van den Ouweland A, Labrijn-Marks I, Olmer R, van der Spaa L, Klijn JG, Meijers-Heijboer H, Dooijes D, Schutte M. Association of rare MSH6 variants with familial breast cancer. Breast Cancer Res Treat. 2009 Nov 19. Hollestelle A, Schutte M. Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma? Cancer Res. 2009 Oct 1;69(19):7893. Schmitt M, Foekens JA. Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells. Breast Cancer Res. 2009;11(5):109. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res. 2009;11(5):R75. Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M. Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations. Breast Cancer Res Treat. 2009 Sep 18. Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C. Improvement of the clinical applicability of the Genomic Grade Index through a qrt-pcr test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009 Sep 10;10:424 Schrohl AS, Look MP, Meijer-van Gelder ME, Foekens JA, Brünner N. Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study. BMC Cancer. 2009 Sep 10;9:322. Klintman M, Ornbjerg Würtz S, Christensen IJ, Bræmer Hertel P, Fernö M, Malmberg M, Mouridsen H, Cold F, Schrohl AS, Foekens JA, Malmström P, Brünner N. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2009 Aug 4. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009 Aug;35(5):463-474. Alles CM, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy J. Meta-analysis and gene enrichment relative to ER status reveal elevated activity of MYC and E2F in the basal breast cancer subgroup.

PloS One 4: e4710 (2009). Wasielweski M, den Bakker MA, Meijer-van gelder ME, van den Ouweland A, Portengen H, Klijn JGM, Meijers-Heijboer H, Foekens JA, Schutte M. CEK21100delC associates with male breast cancer in the Netherlands. Breast Cancer Res Treatm 116: 397-400 (2009). Zhang Y, Sieuwerts AM, Mc Greevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span P, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep CGJ, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA. The 76-Gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treatm 116: 303-309 (2009). Bos PD, Zhang XHF, nadal C, Shu W, Gomis RR, Nguyen D, Minn AJ, van de Vijver MJ, Gerald W, Foekens JA, Massagué J. Genes that mediate breast cancer metastasis through the blood-brain barrier. Nature 459: 1005-1009 (2009). Zhang XHF, Wang Q, Gerals W, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16: 67-78 (2009). Kreike B, Halfwerk H, Amstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten D, Bartelink H, van de Vijver MJ. Local recurrence after breast-conserving therapy in relation to gene expression patterns in large series of patients. Clin Cancer Res 15: 4181-4190 (2009). Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M. Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer. 2009 Jul 16;9:236. Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines. Breast Cancer Res Treat. 2009 Jan;113(2):285-91. Buiting H, Van Delden J, Onwuteaka-Philipsen B, Rietjens J, Rurup M, Van Tol D, Gevers J, Van der Maas P, Van der Heide A. Reporting of euthanasia and physician-assisted suicide in the Netherlands: descriptive study. BMC Med Ethics 2009; 27: 10-18 Rietjens JA, Van Tol DG, Schermer M, Van der Heide A. Judgement of suffering in the case of a euthanasia request in the Netherlands. J Med Ethics 2009; 35: 502-507 Rietjens JA, Buiting HM, Pasman HR, Van der Maas PJ, Van Delden JJ, Van der Heide A. Deciding about continuous deep sedation: physicians perspective: a focus group study. Palliative Med 2009; 23: 410-417 Van Dooren S, Van Veluw H, Van Zuylen L, Rietjens J, Passchier J, Van der Rijt CCD Exploration of concerns of relatives during continuous palliative sedation of their family members with cancer. J Pain Symptom Manage 2009; 38: 452-459 Oldenmenger WH, Sillevis Smitt PAE, Van Dooren S, Stoter G, Van der Rijt CCD.

A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer 2009; 45: 1370-1380 Van Dooren S, Duivenvoorden HJ, Passchier J, Bannink M, Tan MBM, Oldenmenger WH, Seynaeve C, Van der Rijt CCD. The distress thermometer assessed in women at risk of developing hereditary breast cancer. Psycho-oncology 2009; 18: 1080-1087 Rietjens JAC, van der Maas PJ, Onwuteaka-Philipsen BD, Van Delden JJM, Van der Heide A. Two decades of research on euthanasia from the Netherlands. What have we learnt and what questions remain? J Bioeth Inq 2009; 6: 271-283 Van Zuylen L, Van Dijk H, Van Veluw H, Van der Rijt C, Van Dijk G. KNMG-richtlijn Palliatieve sedatie als handzame checklist. Een werkbare variant. Medisch Contact 2009; 64: 1130-1131 Rietjens JAC, Van Zuylen L, Van Veluw RN, Van der Wijk L, Van der Heide A, Van der Rijt CCD. Continue diepe sedatie op een unit voor palliatieve zorg in een kankercentrum: vergelijking tussen patiënten bij wie dit wel en niet werd toegepast voorafgaand aan het overlijden. Ned Tijdschr Palliat Zorg 2009; 9: 11-15 Van Dijk, H, Jongen J, Huygen F, Booms M, Van der Rijt CCD, Van Zuylen L. Zorg over de ziekenhuismuren heen. De waarde van een consultatieteam pijn en palliatieve zorg in een ziekenhuis. Ned Tijdschr Palliat Zorg 2009; 10: 14-16 de Bruijn, P., Moghaddam-Helmantel, I. M., de Jonge, M. J., Meyer, T., Lam, M. H., Verweij, J., Wiemer, E. A., and Loos, W. J. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal, 50: 977-982, 2009. De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Skoneczna, I., Marreaud, S., de Wit, R., and Sylvester, R. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol, 27: 5634-5639, 2009. Eskens, F. A., Steeghs, N., Verweij, J., Bloem, J. L., Christensen, O., van Doorn, L., Ouwerkerk, J., de Jonge, M. J., Nortier, J. W., Kraetzschmar, J., Rajagopalan, P., and Gelderblom, H. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-kit, in patients with advanced or metastatic solid tumors. J Clin Oncol, 27: 4169-4176, 2009. Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., and Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther, 86: 396-402, 2009.

Fitzpatrick, J.M., Sternberg, C.N., Saad, F., Extermann, M., Caffo, O., Halabi, S., Kramer, G., Oudard, S., and de Wit, R. Treatment decisions for advanced genitourinary cancers: from symptoms to risk assessment. Eur Urology, Suppl 8: 738-746, 2009. Ghodgaonkar, M. M., Shah, R. G., Kandan-Kulangara, F., Affar, E. B., Qi, H. H., Wiemer, E., and Shah, G. M. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1. Cell Death Differ, 16: 858-868, 2009. Kitzen, J. J., de Jonge, M. J., Lamers, C. H., Eskens, F. A., van der Biessen, D., van Doorn, L., Ter Steeg, J., Brandely, M., Puozzo, C., and Verweij, J. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer, 45: 1764-1772, 2009. Konings, I. R., Engels, F. K., Sleijfer, S., Verweij, J., Wiemer, E. A., and Loos, W. J. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol, 64: 509-516, 2009. Konings, I. R., Verweij, J., Wiemer, E. A., and Sleijfer, S. The applicability of mtor inhibition in solid tumors. Curr Cancer Drug Targets, 9: 439-450, 2009. Mathijssen, R. H. and Gurney, H. Irinogenetics: how many stars are there in the sky? J Clin Oncol, 27: 2578-2579, 2009. Meulenbeld, H. J., Hamberg, P., and de Wit, R. Chemotherapy in patients with castration-resistant prostate cancer. Eur J Cancer, 45 Suppl 1: 161-171, 2009. Mom, C. H., Verweij, J., Oldenhuis, C. N., Gietema, J. A., Fox, N. L., Miceli, R., Eskens, F. A., Loos, W. J., de Vries, E. G., and Sleijfer, S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res, 15: 5584-5590, 2009. Pothof, J., Verkaik, N. S., van, I. W., Wiemer, E. A., Ta, V. T., van der Horst, G. T., Jaspers, N. G., van Gent, D. C., Hoeijmakers, J. H., and Persengiev, S. P. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. Embo J, 28: 2090-2099, 2009. Steeghs, N., Eskens, F. A., Gelderblom, H., Verweij, J., Nortier, J. W., Ouwerkerk, J., van Noort, C., Mariani, M., Spinelli, R., Carpinelli, P., Laffranchi, B., and de Jonge, M. J. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol, 27: 5094-5101, 2009. Troost, M. M., Sternberg, C. N., and de Wit, R. Management of good risk germ-cell tumours. BJU Int, 104: 1387-1391, 2009.

van Alphen, R. J., Wiemer, E. A., Burger, H., and Eskens, F. A. The spliceosome as target for anticancer treatment. Br J Cancer, 100: 228-232, 2009. van den Belt-Dusebout, A. W., Aleman, B. M., Besseling, G., de Bruin, M. L., Hauptmann, M., van 't Veer, M. B., de Wit, R., Ribot, J. G., Noordijk, E. M., Kerst, J. M., Gietema, J. A., and van Leeuwen, F. E. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys, 75: 1420-1429, 2009. van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K., Mathijssen, R. H., Boven, E., van der Straaten, T., Baak-Pablo, R. F., Wessels, J. A., Guchelaar, H. J., and Gelderblom, H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol, 27: 4406-4412, 2009. van Weerden, W. M., Bangma, C., and de Wit, R. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer, 100: 13-18, 2009. Boonstra JJ, Koppert LB, Wijnhoven BP, Tilanus HW, Van Dekken H, Tran TC, Van der Gaast A. Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. J Surg Oncol. 2009 Oct 1;100(5):407-13 van Meerten E, van der Gaast A, Tilanus HW, Poley JW, Muller K, van Dekken H. Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: the Rotterdam experience. J Surg Oncol. 2009 Jul 1;100(1):32-7. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P, for the RECIST Working Party: Individual patient data analysis to assess modifications to the RECIST criteria Eur J Cancer 45: 248-260, 2009 Verweij J, Therasse P, Eisenhauer EP: Cancer clinical trial outcomes: any progress in tumour-size assessment? Eur J Cancer 45: 225-227, 2009 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancy J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd R, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45: 228-247, 2009 Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubenstein L, Sargent D, Therasse P, Verweij J: Lessons learned from independent central review Eur J Cancer 45: 268-274, 2009 Sleijfer S, Verweij J: The price of success: cost-effectiveness of molecularly targeted agents Clin Pharmacol Ther 85:136-138, 2009 Sparreboom A, Verweij J: Advances in cancer therapeutics Clin Pharmacol Ther 85:113-117, 2009

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Inthibar L, Guastalla J-P, Bachelot T, Perol D, Chabaud S, Hogendoorn P, Cassier P, Dufresne A and Blay J-Y, on behalf of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res 69:5383-5391, 2009 Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay J-Y and Hogendoorn PCW, on behalf of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 15:4191-4198, 2009 Baird RD, Clarke P, Planting A, Kitzen J, Reade S, Reid A, Lyndsey W, Lazaro LL, De las Heras B, Judson IR, Pico C, Kaye SB, Eskens F, Workman P, De Bono JS, Verweij J Phase I safety, pharmacokinetic nad pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24h every 21 days in patients with solid tumours. Mol Cancer Ther 6:1430-1437, 2009 Casali PG, Jost L, Sleijfer S, Verweij J, Blay J-Y on behalf of the ESMO Guidelines Working Group: Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann Oncol 20:132-136, 2009 Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, Van Glabbeke M, Verweij J, Blay J-Y: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC study 62043) J Clin Oncol 27: 3126-3132, 2009 Verweij J: Soft tissue sarcoma trials: one size no longer fits all J Clin Oncol 27: 3085-3087, 2009 Le Cesne A, Van Glabbeke M, Verweij J, Casali P, Findlay M,, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn P, Sciot R, Blay JY: Absence of progression as assessed by Response Evaluation Criteria in Solid Tumors predicts survival in advanced GI stromacel tumors treated with imatinib mesylate: The intergroup EORTC-ISG-AGITG phase III trial J Clin Oncol 27: 3969-3974, 2009 DePrimo SE., Huang X, Blackstein ME, Garrett CR, Harmon CS, Schoffski P, Shah MH Verweij J, Baum CM, Demetri GD: Circulating levels of soluble KIT serve as a biomarker for clinical outcome in Gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clinical Cancer Research 15:5869-5877, 2009 Jager A, Verweij J, Sleijfer S: Adjuvant chemotherapy in older breast cancer patients Nat Rev Clin Oncol 6:563-565, 2009 Hamberg P, Verweij J

Phase I drug combination trial design: walking the tightrope J Clin Oncol 27:4441-4443, 2009 Oosten AW, Seynaeve C, Schmitz PIM, Den Bakker MA, Verweij J, Sleijfer S: Outcomes of first-line chemotherapy in patients with advanced leiomyosarcoma of uterine and nonuterine origin to first-line chemotherapy Sarcoma 2009:348910, 2009 Brooimans RA, Kraan J, Van Putten W, Cornelissen JJ Löwenberg B, Gratama JW Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination Cytometry (Part B), 2009, 76B: 18-26 de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, Sillevis Smitt PA No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Huassociated paraneoplastic neurological syndromes J Neurol 2009, 256:279-82 Lamers CH, Willemsen RA, van Elzakker PM, Gratama JW, Debets R Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors J Immunother 2009, 32:272-9 Strijbos MH, Kraan J, Lamers CH, Sleijfer S, Gratama JW Quantification of circulating endothelial cells by flow cytometry Clin Cancer Res 2009, 15:3640 Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FW, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJ; CURAMA study group Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? Blood Cells Mol Dis 2009, 43: 63-7 Strijbos MH, Verhoef C, Gratama JW, Sleijfer S On the origin of (CD105+) circulating endothelial cells Thromb Haemost. 2009, 102:347-51 Mostert B, Sleijfer S, Foekens JA, Gratama JW Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer Cancer Treat Rev. 2009, 35:463-74 Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells J Natl Cancer Inst, 2009,101:61-66 Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, Ter Steeg J, Brandely M, Puozzo Ch, Verweij J Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumors Eur J Cancer 2009, 45:1764-72 Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon J Natl Cancer Inst 2009, 101: 869-77 Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-relatied quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 2009, 27: 2916-23. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study Clin Cancer Res. 2009, 15:5584-90 Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR Breast Cancer Res Treat. 2009, 118:455-68 Fekkes D, Van Gool AR, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Eggermont AM, Hengeveld MW, Stoter G Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy Amino Acids. 2009, 37:703-8 Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) Eur J Cancer. 2009, 45:3189-97 Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S,Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T Cell Receptor Gene Transfer with Lentiviral Vectors Cancer Res, 2009, 69:9385-94 Hulspas R, O Gorman M, Wood B, Gratama JW, Sutherland DR Considerations for the control of background fluorescence in clinical flow cytometry Cytometry Part B (Clinical Cytometry) 2009; 76B: 355-364 Lambert C, Arroz M, Campos L, Béné MC, Chatelain B, Kappelmayer J, Papa S, Gratama JW Clinical cytometry in Europe, 2009 Cytometry Part B (Clinical Cytometry) 2009; 76B: 408-409 Mandy F, Gratama JW Flow cytometry: a biomedical platform offering diagnostic diversity Cytometry Part B (Clinical Cytometry) 2009; 76B: 365-366 2010 Lammers LA, Mathijssen RHJ, Van Gelder T, Bijl MJ, De Graan A-JM, Seynaeve C, Van Fessem MA, Berns EMJJ, Vulto AG, Van Schaik RHN.

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. British Journal of Cancer (2010) 103, 765 771 Helleman J, Smid M, Jansen MPHM, Van der Burg MEL, Berns EMJJ. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture Gynecologic Oncology 117 (2010) 170 176 Van Jaarsveld MTM, Helleman J, Berns EMJJ, Wiemer EAC. MicroRNAs in ovarian cancer biology and therapy resistance The International Journal of Biochemistry & Cell Biology 42 (2010) 1282 1290 Burger H, Zoumaro-Djayoon A, Boersma AWM, Helleman J, Berns EMJJ, Mathijssen RHJ, Loos WJ, Wiemer EAC. Differential transport of platinum compounds by the human organic cation transporter hoct2 (hslc22a2) British Journal of Pharmacology (2010), 159, 898 908 Helleman J, Jansen MPHM, Burger C, Van der Burg MEL, Berns EMJJ. Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating micrornas The International Journal of Biochemistry & Cell Biology 42 (2010) 25 30 Ruiter R, Bijl MJ, Van Schaik RHN, Berns EMJJ, Hofman A, Coebergh JWW, Van Noord C, Visser LE, Stricker BHCH. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics (2010) 11(10), 1367 1375 Van Agthoven T, Sieuwerts AM, Meijer D, Meijer-Van Gelder ME, Van Agthoven TLA, Sarwari R, Sleijfer S, Foekens JA, Dorssers LCJ. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocrine-Related Cancer (2010) 17 215 230 Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JWM. CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients. BMC Cancer 2010, 10:247 Godinho MFE, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LCJ, Van Agthoven T. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. British Journal of Cancer (2010) 103, 1284 1291 Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2010) 121:53 64 Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M. Four human breast cancer cell lines with biallelic inactivating a-catenin gene mutations.

Breast Cancer Res Treat (2010) 122:125 133 Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction. PLoS One. 2010 Apr 22;5(4):e10312. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang H.

International network of cancer genome projects. Nature. 2010 Apr 15;464(7291):993-8. Klintman M, Ørnbjerg Würtz S, Jarle Christensen Ib, Bræmer Hertel P, Fernö M, Malmberg M, Mouridsen H, Cold F, Schrohl AS, Foekens JA, Malmström P, Brünner N. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat (2010) 121:365 371 Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens JA, Harbeck N, Schmitt M. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers upa and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10(7), 947 962 (2010) Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens JA, Harbeck N. Clinical utility of level-ofevidence-1disease forecast cancer biomarkers upa and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10(8), 1051 1067 (2010) Sieuwerts AM, Ansems M, Look MP, Span PN, de Weerd V, van Galen A, Foekens JA, Adema GJ, Martens JW. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study. Breast Cancer Res. 2010 Dec 1;12(6):R103. [Epub ahead of print] Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T, Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L, Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA, Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T, Johannsson OT, Stefansson K. Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genet. 2010 Jul 22;6(7):e1001029. Hollestelle A, Wasielewski M, Martens JWM, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Current Opinion in Genetics & Development 2010, 20:268 276 Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X, Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH, Cui X. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin Invest. 2011 Jan 4;121(1):212-25. doi: 10.1172/JCI43144. Epub 2010 Dec 1. Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X. FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer. Cancer Res; 70(10) May 15, 2010 Tuna M, Smid M, Zhu D, Martens JW, Amos CI. Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer. PLoS One. 2010 Nov 30;5(11):e15094.

Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological Study of Familial Breast Cancer (EMBRACE), McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix- Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kconfab), Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; Swedish Breast Cancer Study, Sweden (SWE-BRCA), van der Luijt RB, van Os TA, van Leeuwen FE; Hereditary Breast and Ovarian cancer group Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2859-68. Epub 2010 Oct 26. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG; Breast Cancer Susceptibility Collaboration (UK), Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010 Jun;42(6):504-7. Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, Cook M, Oliver C, Frost D; EMBRACE, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Houdayer C; GEMO, Hogervorst FB, Hooning MJ, Ligtenberg MJ; HEBON, Spurdle A, Chenevix-Trench G; kconfab, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Domchek SM, Nathanson KL, Rebbeck TR, Singer CF, Gschwantler-Kaulich D, Dressler C, Fink A, Szabo CI, Zikan M, Foretova L, Claes K, Thomas G, Hoover RN, Hunter DJ, Chanock SJ, Easton DF, Antoniou AC, Couch FJ. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2010 Jul 15;19(14):2886-97. Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, Wijnen JT, Vasen HF, Weiss MM, Klijn JG, Devilee P, Hes FJ, Schutte M. Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. Breast Cancer Res Treat. 2010 Dec;124(3):635-41. Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG. Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene. 2010 Apr 22;29(16):2415-26. Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA; Hereditary Breast and Ovarian Cancer Study, the Netherlands. Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers. Eur J Epidemiol. 2010 Feb;25(2):103-13. Van der Bol JM, de Jong FA, van Schaik RH, Sparreboom A, van Fessem MA, van de Geijn FE, van Daele PL, Verweij J, Sleijfer S, Mathijssen RH. Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. Oncologist. 2010;15(10):1063-72. Epub 2010 Oct 7. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH.

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels. Hypertension. 2010 Oct;56(4):675-81. Epub 2010 Aug 23 Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial. Eur J Cancer. 2010 Dec;46(18):3200-4. Epub 2010 Aug 18. Hamberg P, Verweij J, Sleijfer S. (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor. Oncologist. 2010 15(6):539-47. Epub 2010 May 28. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer. 2010 Aug;46(12):2206-15. Epub 2010 May 13. Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br J Cancer. 2010 Jun 8;102(12):1699-706. Epub 2010 May 18. Strijbos MH, Van Krimpen BA, Debets R, Kraan J, Sleijfer S, Gratama JW, Lamers CHJ. Peripheral blood mrna levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells. Thromb Haemost. 2010 Aug 2;104(2):318-26. Epub 2010 Jun 29. Lalmahomed ZS, Kraan J, Gratama JW, Mostert B, Sleijfer S, Verhoef C. Circulating Tumor Cells and Sample Size: The More, The Better. J Clin Oncol. 2010 Jun 10;28(17):e288-9; author reply e290. Epub 2010 May 3. Strijbos MH, Gratama JW, Schmitz PIM, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LWMM, Sleijfer S. Circulating endothelial cells, circulating tumor cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel Eur J Cancer. 2010 Jul;46(11):2027-35. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther. 2010 Apr;10(4):547-62. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE. Two-protein signature of novel serological markers apolipoprotein-a2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol. 2010 Jul;21(7):1472-81. Epub 2009 Dec 18. De Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

J Pharm Biomed Anal. 2010 Mar 11;51(4):934-41. Epub 2009 Oct 31. Boere IA, Hamberg P, Sleijfer S. It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci. 2010 Jan;101(1):7-15. Epub 2009 Sep 18. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010 Jan;46(1):72-83. Epub Heemskerk-Gerritsen BA, Kriege M, Seynaeve C. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers. JAMA. 2010 Dec 22;304(24):2695; author reply 2695-6 Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B; SWE-BRCA, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L; GEMO, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat- Bouvet L; GEMO, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; kconfab, Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 1;70(23):9742-54. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG. BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. J Clin Oncol. 2010 Dec 20;28(36):5265-73 Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M,

Sobol H, Longy M, Frenay M, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE; HEBON Study Collaborators, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldés T, de la Hoya M, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Toland AE, Montagna M, D'Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H; kconfab, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MI, Mai PL, Osorio A, Durán M, Andres R, Benítez J, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix- Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, Offit K, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Sinilnikova O, Barjhoux L, Giraud S, Léone M, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C, Moncoutier V, Belotti M, de Pauw A, Bressac-de-Paillerets B, Remenieras A, Byrde V, Caron O, Lenoir G, Bignon YJ, Uhrhammer N, Lasset C, Bonadona V, Hardouin A, Berthet P, Sobol H, Bourdon V, Noguchi T, Eisinger F, Coulet F, Colas C, Soubrier F, Coupier I, Peyrat JP, Fournier J, Révillion F, Vennin P, Adenis C, Rouleau E, Lidereau R, Demange L, Nogues C, Muller D, Fricker JP, Longy M, Sevenet N, Toulas C, Guimbaud R, Gladieff L, Feillel V, Leroux D, Dreyfus H, Rebischung C, Cassini C, Faivre L, Prieur F, Ferrer SF, Frénay M, Vénat- Bouvet L, Lynch HT, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE, Hogervorst FB, Verhoef S, Verheus M, van 't Veer LJ, van Leeuwen FE, Rookus MA, Collée M, van den Ouweland AM, Jager A, Hooning MJ, Tilanus-Linthorst MM, Seynaeve C, van Asperen CJ, Wijnen JT, Vreeswijk MP, Tollenaar RA, Devilee P, Ligtenberg MJ, Hoogerbrugge N, Ausems MG, van der Luijt RB, Aalfs CM, van Os TA, Gille JJ, Waisfisz Q, Meijers-Heijboer H, Gomez-Garcia EB, van Roozendaal CE, Blok MJ, Oosterwijk JC, van der Hout AH, Mourits MJ, Vasen HF, Spurdle AB, Chenevix-Trench G. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010 Oct 28;6(10):e1001183 Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Waltes R, Bremer M, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Humphreys K, Liu J, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G; kconfab Investigators; AOCS Group, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U; GENICA Consortium, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benítez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J; Breast Cancer Association Consortium. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2143-51 Van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg. 2010 May;97(5):671-9. Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL, Arias JI, Menéndez P, Benítez J, Chang-Claude J, Hein R, Wang- Gohrke S, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kosma VM, Kataja V; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Beesley

J, Chen X, Chenevix-Trench G, Couch FJ, Olson JE, Fredericksen ZS, Wang X, Giles GG, Severi G, Baglietto L, Southey MC, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Lissowska J, Sherman ME, Bolton KL, Hall P, Czene K, Cox A, Brock IW, Elliott GC, Reed MW, Greenberg D, Anton-Culver H, Ziogas A, Humphreys M, Easton DF, Caporaso NE, Pharoah PD. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptornegative breast cancer survival. J Natl Cancer Inst. 2010 May 5;102(9):650-62. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010 Mar 10;28(8):1294-300 Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010 Nov;76(2):133-41 Van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Ann Oncol. 2010 May;21(5):974-82 Schilder CM, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB. The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology. 2010 Apr;19(4):415-22. Damen TH, Timman R, Kunst EH, Gopie JP, Bresser PJ, Seynaeve C, Menke-Pluijmers MB, Mureau MA, Hofer SO, Tibben A. High satisfaction rates in women after DIEP flap breast reconstruction. J Plast Reconstr Aesthet Surg. 2010 Jan;63(1):93-100 Obdeijn, I. M., Loo, C. E., Rijnsburger, A. J., Wasser, M. N., Bergers, E., Kok, T., Klijn, J. G., & Boetes, C. 2010. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat., 119(2): 399-407. Walker, L. C., Fredericksen, Z. S., Wang, X., Tarrell, R., Pankratz, V. S., Lindor, N. M., Beesley, J., Healey, S., Chen, X., Stoppa-Lyonnet, D., Tirapo, C., Giraud, S., Mazoyer, S., Muller, D., Fricker, J. P., Delnatte, C., Schmutzler, R. K., Wappenschmidt, B., Engel, C., Schonbuchner, I., Deissler, H., Meindl, A., Hogervorst, F. B., Verheus, M., Hooning, M. J., van den Ouweland, A. M., Nelen, M. R., Ausems, M. G., Aalfs, C. M., van Asperen, C. J., Devilee, P., Gerrits, M. M., Waisfisz, Q., Szabo, C. I., Easton, D. F., Peock, S., Cook, M., Oliver, C. T., Frost, D., Harrington, P., Evans, D. G., Lalloo, F., Eeles, R., Izatt, L., Chu, C., Davidson, R., Eccles, D., Ong, K. R., Cook, J., Rebbeck, T., Nathanson, K. L., Domchek, S. M., Singer, C. F., Gschwantler-Kaulich, D., Dressler, A. C., Pfeiler, G., Godwin, A. K., Heikkinen, T., Nevanlinna, H., Agnarsson, B. A., Caligo, M. A., Olsson, H., Kristoffersson, U., Liljegren, A., Arver, B., Karlsson, P., Melin, B., Sinilnikova, O. M., McGuffog, L., Antoniou, A. C., Chenevix-Trench, G., Spurdle, A. B., & Couch, F. J. 2010. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res, 12(6): R102.